Gene Therapy最新文献

Correction: RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells.

IF 4.6 3区医学

Gene Therapy Pub Date : 2024-12-20 DOI: 10.1038/s41434-024-00487-5

Lucie Bouquet, Elodie Bôle-Richard, Walid Warda, Mathieu Neto Da Rocha, Rim Trad, Clémentine Nicod, Rafik Haderbache, Delphine Genin, Christophe Ferrand, Marina Deschamps

引用次数: 0

AAV library screening identifies novel vector for efficient transduction of human aorta.

IF 4.6 3区医学

Gene Therapy Pub Date : 2024-12-18 DOI: 10.1038/s41434-024-00511-8

Lena C Schröder, Leonard Hüttermann, Anca Kliesow Remes, Jakob C Voran, Susanne Hille, Wiebke Sommer, Georg Lutter, Gregor Warnecke, Derk Frank, Dennis Schade, Oliver J Müller

{"title":"AAV library screening identifies novel vector for efficient transduction of human aorta.","authors":"Lena C Schröder, Leonard Hüttermann, Anca Kliesow Remes, Jakob C Voran, Susanne Hille, Wiebke Sommer, Georg Lutter, Gregor Warnecke, Derk Frank, Dennis Schade, Oliver J Müller","doi":"10.1038/s41434-024-00511-8","DOIUrl":"https://doi.org/10.1038/s41434-024-00511-8","url":null,"abstract":"Targeted gene delivery to vascular smooth muscle cells (VSMCs) could prevent or improve a variety of diseases affecting the vasculature and particularly the aorta. Thus, we aimed to develop a delivery vector that efficiently targets VSMCs. We selected engineered adeno-associated virus (AAV) capsids from a random AAV capsid library and tested the top enriched motifs in parallel screening through individual barcoding. This approach allowed us to distinguish capsids that only transduce cells based on genomic DNA (gDNA) from those also mediating transgene expression based on transcribed cDNA reads. After three rounds of selection on primary murine VSMCs (mVSMCs), we identified a novel targeting motif (RFTEKPA) that significantly improved transduction and gene expression efficiency over AAV9-wild type (WT) and increased expression in mVSMCs by 70% compared to the previously identified SLRSPPS peptide. Further analysis showed that the novel motif also improved expression in human aortic smooth muscle cells (HAoSMCs) and human aortic tissue ex vivo up to threefold compared to SLRSPPS and approximately 70-fold to AAV9-WT. This high cross-species transduction efficiency makes the novel capsid motif a potential candidate for future clinical application in vascular diseases.","PeriodicalId":12699,"journal":{"name":"Gene Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intracisternal vs intraventricular injection of AAV1 result in comparable, widespread transduction of the dog brain. 胸腔内注射 AAV1 与脑室内注射 AAV1 在狗脑中产生的广泛转导效果相当。

IF 4.6 3区医学

Gene Therapy Pub Date : 2024-12-09 DOI: 10.1038/s41434-024-00510-9

Jacqueline E Hunter, Charles H Vite, Caitlyn M Molony, Patricia A O'Donnell, John H Wolfe

{"title":"Intracisternal vs intraventricular injection of AAV1 result in comparable, widespread transduction of the dog brain.","authors":"Jacqueline E Hunter, Charles H Vite, Caitlyn M Molony, Patricia A O'Donnell, John H Wolfe","doi":"10.1038/s41434-024-00510-9","DOIUrl":"https://doi.org/10.1038/s41434-024-00510-9","url":null,"abstract":"Widespread distribution of transduced brain cells following delivery of AAV vectors into the cerebrospinal fluid (CSF) of the cisterna magna (CM) has been demonstrated in large animal brains. In humans, intraventricular injection is preferred to intracisternal injection for CSF delivery due to the risk of brain stem injury. One study in the dog reported adverse reactions to AAV vectors expressing GFP injected into the lateral ventricle but not when injected into the CM. In contrast, AAV expressing mammalian genes in diseased animals have not triggered adverse responses since many genetic diseases also have compromised immune systems. Differences in circulation of CSF from each site could potentially affect vector spread within the brain, but a direct comparison has not been made using both a mammalian gene and immunologically normal animals. In this study we evaluated the dopamine-2-receptor (D2R) variant D2R80A, which is inactivated for intracellular signaling and has been used as a reporter gene in large animal brains. No adverse reactions to the D2R80A gene were observed from either injection route in normal dogs and both routes resulted in comparable distribution of D2R80A within the brain.","PeriodicalId":12699,"journal":{"name":"Gene Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unlocking patient access to gene therapy: five key practices.

IF 4.6 3区医学

Gene Therapy Pub Date : 2024-12-06 DOI: 10.1038/s41434-024-00509-2

Tay Salimullah, Burcu Kazazoglu Taylor, Madeleine Zerbato

引用次数: 0

Placental nanoparticle-mediated IGF1 gene therapy corrects fetal growth restriction in a guinea pig model.

IF 4.6 3区医学

Gene Therapy Pub Date : 2024-12-04 DOI: 10.1038/s41434-024-00508-3

Baylea N Davenport, Rebecca L Wilson, Alyssa A Williams, Helen N Jones

{"title":"Placental nanoparticle-mediated IGF1 gene therapy corrects fetal growth restriction in a guinea pig model.","authors":"Baylea N Davenport, Rebecca L Wilson, Alyssa A Williams, Helen N Jones","doi":"10.1038/s41434-024-00508-3","DOIUrl":"10.1038/s41434-024-00508-3","url":null,"abstract":"Fetal growth restriction (FGR) caused by placental insufficiency is a major contributor to neonatal morbidity and mortality. There is currently no in utero treatment for placental insufficiency or FGR. The placenta serves as the vital communication, supply, exchange, and defense organ for the developing fetus and offers an excellent opportunity for therapeutic interventions. Here we show efficacy of repeated treatments of trophoblast-specific human insulin-like 1 growth factor (IGF1) gene therapy delivered in a non-viral, polymer nanoparticle to the placenta for the treatment of FGR. Using a guinea pig maternal nutrient restriction model (70% food intake) of FGR, nanoparticle-mediated IGF1 treatment was delivered to the placenta via ultrasound guidance across the second half of pregnancy, after establishment of FGR. This treatment resulted in correction of fetal weight in MNR + IGF1 animals compared to sham treated controls on an ad libitum diet, increased fetal blood glucose and decreased fetal blood cortisol levels compared to sham treated MNR, and showed no negative maternal side-effects. Overall, we show a therapy capable of positively impacting the entire pregnancy environment: maternal, placental, and fetal. This combined with our previous studies using this therapy at mid pregnancy in the guinea pig and in two different mouse model and three different human in vitro/ex vivo models, demonstrate the plausibility of this therapy for future human translation. Our overall goal is to improve health outcomes of neonates and decrease numerous morbidities associated with the developmental origins of disease.","PeriodicalId":12699,"journal":{"name":"Gene Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adeno-associated virus serotype 2 capsids with proteolytic cuts by trypsin remain intact and potent.

IF 4.6 3区医学

Gene Therapy Pub Date : 2024-11-29 DOI: 10.1038/s41434-024-00507-4

Yu Zhou, Tina Sach, Joseph Y Ong, Ting-An Lim, Zoltan Berecz, Colin Deniston, Goran Milicic, Connie Y Tsai, Taryn Kandepalli, Derek J Langeslay, Qiang Qin

{"title":"Adeno-associated virus serotype 2 capsids with proteolytic cuts by trypsin remain intact and potent.","authors":"Yu Zhou, Tina Sach, Joseph Y Ong, Ting-An Lim, Zoltan Berecz, Colin Deniston, Goran Milicic, Connie Y Tsai, Taryn Kandepalli, Derek J Langeslay, Qiang Qin","doi":"10.1038/s41434-024-00507-4","DOIUrl":"https://doi.org/10.1038/s41434-024-00507-4","url":null,"abstract":"Recombinant adeno-associated viral (AAV) vectors have emerged as prominent gene delivery vehicles for gene therapy. In the journey of an AAV vector, AAV vectors can be exposed to different proteolytic environments inside the production cells, during the cell lysis step, within the endosome, and finally inside the cell nucleus. The stability of a modified AAV serotype 2 (AAV2) capsid was evaluated via a proteolytic approach using trypsin and other proteases and both denaturing and non-denaturing analytical methods. Trypsin digestion of the AAV2 capsids resulted in clips of the capsid proteins at the C-terminus as confirmed by denaturing methods including SDS-PAGE, CE-SDS, Western blot, and RPLC-MS. It was found that the AAV2 capsid with clips not only remains structurally intact, as confirmed by non-denaturing methods including SEC, thermostability testing, and cryo-EM, but also remains potent, as confirmed in a cell-based potency assay. This finding reveals that AAV2 capsid with proteolytic cuts remains intact and potent since the icosahedral three-dimensional structural arrangement of AAV capsid proteins can protect the clipped fragment from being released from the capsid, such that the AAV capsid remains intact allowing for the functionality to be maintained to deliver the DNA in the host cell. Evaluation of AAV stability using a proteolytic approach and multiple denaturing and non-denaturing analytical methods can provide valuable information for engineering AAV capsids to develop AAV-based gene therapy.","PeriodicalId":12699,"journal":{"name":"Gene Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142754970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prime editing: therapeutic advances and mechanistic insights.

IF 4.6 3区医学

Gene Therapy Pub Date : 2024-11-28 DOI: 10.1038/s41434-024-00499-1

Joss B Murray, Patrick T Harrison, Janine Scholefield

{"title":"Prime editing: therapeutic advances and mechanistic insights.","authors":"Joss B Murray, Patrick T Harrison, Janine Scholefield","doi":"10.1038/s41434-024-00499-1","DOIUrl":"https://doi.org/10.1038/s41434-024-00499-1","url":null,"abstract":"We are often confronted with a simple question, \"which gene editing technique is the best?\"; the simple answer is \"there isn't one\". In 2021, a year after prime editing first made its mark, we evaluated the landscape of this potentially transformative advance in genome engineering towards getting treatments to the clinic [1]. Nearly 20% of the papers we cited were still in pre-print at the time which serves to indicate how early-stage the knowledge base was at that time. Now, three years later, we take a look at the landscape and ask what has been learnt to ensure this tech is broadly accessible, highlighting some key advances, especially those that push this towards the clinic. A big part of the appeal of prime editing is its ability to precisely edit DNA without double stranded breaks, and to install any of the 12 possible single-nucleotide conversion events as well as small insertions and/or deletions, or essentially any combination thereof. Over the last few decades, other transformative and Nobel prize-winning technologies that rely on Watson-Crick base-pairing such as PCR, site-directed mutagenesis, RNA interference, and one might say, \"classic\" CRISPR, were swiftly adopted across labs around the world because of the speed with which mechanistic rules governing their efficiency were determined. Whilst this perspective focuses on the context of gene therapy applications of prime editing, we also further look at the recent studies which have increased our understanding of the mechanism of PEs and simultaneously improved the efficiency and diversity of the PE toolbox.","PeriodicalId":12699,"journal":{"name":"Gene Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gene-based therapy for the treatment of spinal muscular atrophy types 1 and 2 : a systematic review and meta-analysis. 治疗脊髓性肌萎缩症 1 型和 2 型的基因疗法：系统综述和荟萃分析。

IF 4.6 3区医学

Gene Therapy Pub Date : 2024-11-27 DOI: 10.1038/s41434-024-00503-8

Bunchai Chongmelaxme, Varalee Yodsurang, Ponlawat Vichayachaipat, Thanate Srimatimanon, Oranee Sanmaneechai

{"title":"Gene-based therapy for the treatment of spinal muscular atrophy types 1 and 2 : a systematic review and meta-analysis.","authors":"Bunchai Chongmelaxme, Varalee Yodsurang, Ponlawat Vichayachaipat, Thanate Srimatimanon, Oranee Sanmaneechai","doi":"10.1038/s41434-024-00503-8","DOIUrl":"https://doi.org/10.1038/s41434-024-00503-8","url":null,"abstract":"Despite numerous studies identifying the advantages of therapies for spinal muscular atrophy (SMA), healthcare professionals encounter obstacles in determining the most effective treatment. This study aimed to investigate the effects of gene-based therapy for SMA. A systematic search was conducted from inception to May 2024 across databases, and all studies assessing the effects of gene-based therapy on patients with SMA types 1 and 2 were included. The outcomes measured were survival, the need for ventilatory support, improvements in motor function, and the occurrence of adverse drug reactions. Meta-analyses were performed using a random-effects model. A total of 57 studies (n = 3418) were included, and the meta-analyses revealed that onasemnogene abeparvovec showed the highest survival rate (95% [95% CI: 88, 100]), followed by risdiplam (86% [95% CI: 76, 94]) and nusinersen (60% [95% CI: 50, 70]). The number of patients needing ventilatory support was reduced after treatment with onasemnogene abeparvovec (risk ratio = 0·10 [95% CI: 0·02, 0·53]). Onasemnogene abeparvovec and risdiplam had similar proportions of patients with improvements in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders score of ≥4 points (92% [95% CI: 62, 100] vs 90% [95% CI: 77, 97]). In contrast, nusinersen had the smallest improvement (74% [95% CI: 66, 81]). The most frequently observed adverse drug reactions were headaches, vomiting, and gastrointestinal disorders. Gene-based therapy benefits patient survival and improves motor function. Onasemnogene abeparvovec and risdiplam appear highly effective, whereas nusinersen exhibits moderate effectiveness.","PeriodicalId":12699,"journal":{"name":"Gene Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PCRX-201, a novel IL-1Ra gene therapy treatment approach for low back pain resulting from intervertebral disc degeneration. PCRX-201 是一种新型 IL-1Ra 基因疗法，用于治疗椎间盘退变引起的腰背痛。

IF 4.6 3区医学

Gene Therapy Pub Date : 2024-11-21 DOI: 10.1038/s41434-024-00504-7

Joseph W Snuggs, Rebecca K Senter, Joshua P Whitt, J Derek Jackson, Christine L Le Maitre

{"title":"PCRX-201, a novel IL-1Ra gene therapy treatment approach for low back pain resulting from intervertebral disc degeneration.","authors":"Joseph W Snuggs, Rebecca K Senter, Joshua P Whitt, J Derek Jackson, Christine L Le Maitre","doi":"10.1038/s41434-024-00504-7","DOIUrl":"10.1038/s41434-024-00504-7","url":null,"abstract":"Low back pain is the leading cause of global disability with intervertebral disc (IVD) degeneration a major cause. However, no current treatments target the underlying pathophysiological causes. PCRX-201 presents a novel gene therapy approach that addresses this issue. PCRX-201 codes for interleukin-1 receptor antagonist, the signalling inhibitor of the pro-inflammatory cytokine interleukin-1, which orchestrates the catabolic degeneration of the IVD. Here, the ability of PCRX-201 to transduce human nucleus pulposus cells to increase IL-1Ra production was assessed together with effects on catabolic pathways. When transduced with PCRX-201, the production and release of IL-1Ra was increased in degenerate human nucleus pulposus cells and tissue. Whereas, the production of downstream proteins, including IL-1β, IL-6, MMP3, ADAMTS4 and VEGF were decreased in both cells and tissue, indicating a reduction in IL-1-induced catabolic signalling. Here, a novel gene therapy vector, PCRX-201, was shown to transduce degenerate NP cells and tissue, increasing the production of IL-1Ra. The increased IL-1Ra resulted in decreased production of catabolic cytokines, enzymes and angiogenic factors, whilst also increasing aggrecan expression. This demonstrates PCRX-201 enables the inhibition of IL-1-driven IVD degeneration. The ability of PCRX-201 to elicit anti-catabolic responses is promising and warrants further development to determine the efficacy of this exciting, novel gene therapy.","PeriodicalId":12699,"journal":{"name":"Gene Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bridging gene therapy and next-generation vaccine technologies. 连接基因治疗和新一代疫苗技术。

IF 4.6 3区医学

Gene Therapy Pub Date : 2024-11-18 DOI: 10.1038/s41434-024-00502-9

Kristie Bloom, Abdullah Ely, Mohube Betty Maepa, Patrick Arbuthnot

引用次数: 0